Q-omics provides the consensus-scored NHSL1 profile across patient tissues and cancer cell-line models. NHSL1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NHSL1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, NHSL1 protein abundance shows 18,845 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KICH, and LSCC as cancer lineages where NHSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NHSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NHSL1 survival associations across molecular data types. NHSL1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NHSL1 RNA expression–survival associations across cancer types. High NHSL1 expression shows unfavorable associations in BLCA, SKCM and LUAD, but favorable associations in SCLC, UVM and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for NHSL1 RNA expression.
This table summarizes NHSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NHSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NHSL1 shows lower tumor expression in KICH, KIRC, LUAD, KIRP and COAD and higher tumor expression in BLCA. The KICH box plot shows higher NHSL1 RNA expression in normal versus tumor tissue (log2 FC = −2.486, t-test p < 0.001).
This table shows molecular features associated with NHSL1 in patient tissues and cancer cell lines. In patient samples, NHSL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NHSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
